Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 5/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | BAX | Q07812 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789800 | 0.85 | CA1 (0.55) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL3789913 | 0.82 | MAOB (0.47) | CA1CA2ENPP2MAOBMAOA | |
| SCHEMBL15156136 | 0.81 | CA1 (0.55) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL20600 | 0.80 | ENPP2 (0.59) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL29889491 | 0.80 | ENPP2 (0.59) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL13857858 | 0.80 | CA1 (0.53) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL3790117 | 0.80 | CA1 (0.53) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL11576951 | 0.78 | LTA4H (0.55) | LTA4HNR1H2BAXTSHRL3MBTL1 | |
| SCHEMBL31050822 | 0.78 | CA1 (0.55) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL13857937 | 0.76 | CA1 (0.53) | CA1CA2LTA4HNR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CA1 3273/4885CA2 1992/4885LTA4H 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.